Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Agrees to comply with the study procedures and provides written informed consent~* 18 to 64 years of age~* Body mass index between 18 and 30 kg/m2~* Negative urine pregnancy test at the Screening visit and the day of each vaccination.~* Female subjects must either be of non-childbearing potential or use highly effective methods of contraception from at least 2 months before the Screening Visit through 3 weeks post last vaccination~* In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination~Exclusion~* Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care~* Administration of an investigational product within 45 days~* Women who are pregnant or breastfeeding, or plan to become pregnant during the study~* Prior administration of investigational agent using formulations similar to VAL-506440~* History of a serious reaction to prior influenza vaccinations~* History of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine~* Administration of any live attenuated vaccines within 4 weeks before enrollment, inactive vaccines within 2 weeks before enrollment, or plans to any vaccine within the vaccination period~* Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination~* Any chronic administration of immunosuppressant or other immune-modifying drugs within 6 months prior to administration of study vaccine~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.~* Any acute disease at the time of enrollment~* Any bleeding risk or thromboembolic event or any related medical history~* Regular alcohol consumption \> 3 units/day, or current user of any illicit drugs, or has a history of drug/alcohol abuse with 1 year of screening or has a positive urine drug/alcohol test at screening~* Persons employed in a capacity that involves handling poultry or wild birds~* Unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies within 4 weeks before administration of the first vaccination, throughout the study~* Had major surgery or donation of blood or blood products within 4 weeks of dosing~* Current smoking of more than 10 cigarettes (or equivalent amount of tobacco) per day, and within 3 months prior to Screening~* Subject is an employee of the Sponsor or CRO involved in the study.~* Vulnerable subjects (e.g., a subject kept in detention).~* Any condition, that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of the study results~* History of autoimmune disease~* Inadequate Liver Function as defined by AST, ALT, GGT, alkaline phosphatase and bilirubin \> 1.5xULN~* Known allergy or history of anaphylaxis or other serious adverse reactions to any of the constituents of the study vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- VAL-506440 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete